drugset / Trial / NCT04530357
Reactogenicity, Safety and Immunogenicity of QazCovid-in® COVID-19 Vaccine
Phase 1/2
Completed
244 enrolled
Research Institute for Biological Safety Problems
National Scientific Center for Phthisiopulmonology of the Republic of Kazakhstan · collab
RandomizedParallel-groupSingle-blindPrevention
Summary
Randomized, blind, placebo-controlled phase- i study and randomized, open phase phase-ii study of QAZCOVID-IN®- COVID-19 inactivated vaccine in healthy adult volunteers from 18 years old and elder
Timeline
- Start
- 2020-09-19
- Primary completion
- 2020-11-25
- Completion
- 2021-04-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QazCovid-in® | Vaccine | 0.5 ml | Intramuscular |